- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05023980
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)
April 4, 2024 updated by: Loxo Oncology, Inc.
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL who have not been treated.
Participation could last up to five years.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
250
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Patient Advocacy
- Phone Number: 1-855-LOXO-305
- Email: clinicaltrials@loxooncology.com
Study Locations
-
-
New South Wales
-
Liverpool, New South Wales, Australia, 2170
- Liverpool Hospital
-
Wentworthville, New South Wales, Australia, 2145
- Westmead Hospital
-
-
Victoria
-
Frankston, Victoria, Australia, 3199
- Peninsula Private Hospital
-
-
-
-
-
Salzburg, Austria, 5020
- Uniklinikum Salzburg
-
Vienna, Austria, 1160
- Klinik Ottakring
-
-
-
-
Paraná
-
Curitiba, Paraná, Brazil, 80810050
- Centro Integrado de Oncologia de Curitiba
-
-
Rio Grande Do Sul
-
Passo Fundo, Rio Grande Do Sul, Brazil, 99010090
- Instituto do Câncer - Hospital São Vicente de Paulo
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90050-170
- Irmandade da Santa Casa de Misericórdia de Porto Alegre
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90110270
- Centro Gaucho Integrado - Mae de Deus Center
-
-
São Paulo
-
Campinas, São Paulo, Brazil, 13083-878
- Hemocentro Unicamp
-
Jaú, São Paulo, Brazil, 17210120
- Fundacao Doutor Amaral Carvalho
-
-
-
-
-
Plovdiv, Bulgaria, 4000
- UMHAT "Sveti Georgi" EAD
-
Sofia, Bulgaria, 1431
- UMHAT 'Sv. Ivan Rilski', EAD
-
Sofia, Bulgaria, 1797
- "SHATHD" EAD, Sofia
-
Stara Zagora, Bulgaria, 6003
- UMHAT - Prof. Dr. Stoyan Kirkovich" AD
-
-
-
-
-
Beijing, China, 100730
- Beijing Hospital
-
Chongqing, China, 400030
- Chongqing Cancer Hospital
-
Haikou, China, 570311
- Hainan General Hospital
-
Zhengzhou, China, 450008
- Henan Cancer Hospital
-
-
Anhui
-
Hefei, Anhui, China, 233004
- Anhui Provincial Cancer Hospital
-
-
Beijing
-
Beijing, Beijing, China, 100034
- Peking University first hospital
-
Beijing, Beijing, China, 100191
- Peking University Third Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- The First Affiliated Hospital of Guangzhou Medical University
-
Guangzhou, Guangdong, China, 510000
- Cancer Center of Guangzhou Medical University
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Hunan Cancer Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- The First Affiliated Hospital Of Nanchang University
-
-
Liaoning
-
Shenyany, Liaoning, China, 110022
- Shengjing Hospital of China Medical University
-
-
Nanjing
-
Nanjing, Nanjing, China, 210029
- Jiangsu Province Hospital
-
-
Shanghai
-
Changning District, Shanghai, China, 200050
- shanghai Tongren hospital
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital of Sichuan University
-
-
Tianjin
-
Tianjin, Tianjin, China, 300060
- Tianjin Medical University Cancer Institute and Hospital
-
Tianjin, Tianjin, China, 300020
- Institute of hematology&blood disease hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 311100
- The First People's Hospital of Hangzhou Linping District
-
-
-
-
-
Brno, Czechia, 62500
- Fakultni nemocnice Brno
-
Hradec Kralove, Czechia, 500 05
- Fakultni nemocnice Hradec Kralove
-
Praha 10, Czechia, 100 34
- Fakultni nemocnice Kralovske Vinohrady
-
Praha 2, Czechia, 12808
- Vseobecna Fakultni Nemocnice V Praze
-
-
-
-
-
Le Mans, France, 72000
- Hospitalier Le Mans
-
Nimes, France, 30900
- Chu Nimes/Institut De Cancerologie Du Gard
-
-
Tours Cedex 9
-
Tours, Tours Cedex 9, France, 37044
- CHRU De Tours
-
-
Vendee
-
La Roche-sur-Yon, Vendee, France, 85000
- CHD Vendee
-
-
-
-
-
Budapest, Hungary, 1088
- Semmelweis Egyetem
-
Budapest, Hungary, 1122
- National Institute of Oncology
-
Budapest, Hungary, 1097
- Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
-
Debrecen, Hungary, 4032
- Debreceni Egyetem Orvos-es Egészsegtudomanyi Centrum
-
Nyíregyháza, Hungary, 4400
- SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
-
Székesfehérvár, Hungary, 8000
- Fejér Megyei Szent György Egyetemi Oktató Kórház
-
-
-
-
-
Dublin 7, Ireland
- Mater Misericordiae Hospital
-
-
-
-
-
Bergamo, Italy, 24127
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
-
Brescia, Italy, 25123
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
-
Firenze, Italy, 50134
- Azienda Ospedaliera Universitaria Careggi
-
Meldola, Italy, 47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
Milano, Italy, 20122
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
Milano, Italy, 20162
- ASST Grande Ospedale Metropolitano Niguarda Comitato Etico Milano Area C
-
Monza, Italy, 20900
- Azienda Socio Sanitaria Territoriale Di Monza (Presidio San Gerardo)
-
Novara, Italy, 28100
- Azienda Ospedale Maggiore Della Carita
-
Palermo, Italy, 90146
- Azienda Ospedaliera Vincenzo Cervello
-
Perugia, Italy, 06132
- Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich)
-
Ravenna, Italy, 48020
- Ospedale Santa Maria delle Croci
-
Roma, Italy, 00168
- Fondazione Policlinico Universitario Agostino Gemelli
-
Terni, Italy, 05100
- Azienda Ospedaliera Santa Maria Terni
-
Torino, Italy, 10126
- A.O.U. Citta' della Salute e della Scienza di Torino
-
Tricase (Le), Italy, 73039
- Azienda Ospedaliera Card. G. Panico
-
Trieste, Italy, 34125
- Azienda sanitaria integrata università di Trieste
-
-
BO
-
Bologna, BO, Italy, 40138
- IRCCS - AOU di Bologna
-
-
PI
-
Pisa, PI, Italy, 56126
- Azienda Ospedaliero Universitaria Pisana
-
-
Potenza
-
Rionero In Vulture, Potenza, Italy, 85028
- Irccs Crob
-
-
-
-
-
Fukoka-ken, Japan, 806 8501
- JCHO Kyushu Hospital
-
Kagoshima, Japan, 890-8520
- Kagoshima University Hospital
-
Okayama, Japan, 700-8558
- Okayama University Hospital
-
-
Aichi
-
Nagoya, Aichi, Japan, 467-8602
- Nagoya City University Hospital
-
Nagoya, Aichi, Japan, 460-0001
- Nagoya Medical Center
-
-
Chiba
-
Chiba-Shi, Chiba, Japan, 260-8717
- Chiba Cancer Center
-
-
Fukui
-
Yoshida-Gun, Fukui, Japan, 910-1193
- Fukui Medical University Hospital
-
-
Fukuoka
-
Kitakyushu-shi, Fukuoka, Japan, 807 8556
- Hospital of University of Occupational and Environmental Health
-
-
Fukuoka-Ken
-
Kurume-shi, Fukuoka-Ken, Japan, 830 8543
- Our Lady of the Snow St. Mary's Hospital
-
-
HigaShiibaraki-Gun
-
Ibaraki-machi, HigaShiibaraki-Gun, Japan, 311 3193
- NHO Mito Medical Center
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 060-8648
- Hokkaido University Hospital
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 241-8515
- Kanagawa Cancer Center
-
-
Kochi
-
Nankoku, Kochi, Japan, 783-8505
- Kochi Medical School Hospital
-
-
Miyagi
-
Sendai-shi, Miyagi, Japan, 980-8574
- Tohoku University Hospital
-
-
Saitama
-
Kawagoe, Saitama, Japan, 350-8550
- Saitama Medical Center
-
Koshigaya, Saitama, Japan, 343 8555
- Dokkyo Medical University - Koshigaya Hospital
-
-
Yamanshi
-
Chuo, Yamanshi, Japan, 409-3821
- University of Yamanashi Hospital
-
-
-
-
-
Busan, Korea, Republic of, 47392
- Inje Univ Busan Paik Hospital
-
-
Incheon-gwangyeoksi [Incheon]
-
Namdong-gu, Incheon-gwangyeoksi [Incheon], Korea, Republic of, 21565
- Gachon University Gil Medical Center
-
-
Seoul
-
Seocho-Gu, Seoul, Korea, Republic of, 06591
- The Catholic University of Korea-Seoul St. Mary's Hospital
-
-
Seoul, Korea
-
Seoul, Seoul, Korea, Korea, Republic of, 03080
- Seoul National University Hospital
-
-
Seoul-teukbyeolsi [Seoul]
-
Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of, 06351
- Samsung Medical Center
-
Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of, 03722
- Severance Hospital, Yonsei University Health System
-
-
-
-
-
Christchurch, New Zealand, 8011
- Christchurch Hospital
-
Papatoetoe, New Zealand, 2025
- Middlemore Clinical Trials
-
-
Auckland
-
Takapuna, Auckland, New Zealand, 0622
- North Shore Hospital, Haematology Research
-
-
Bay Of Plenty
-
Tauranga, Bay Of Plenty, New Zealand, 3112
- Tauranga Hospital
-
-
-
-
-
Biała Podlaska, Poland, 21500
- KO-MED Centra Kliniczne
-
Bydgoszcz, Poland, 85-168
- Szpital Uniwersytecki nr 2 im. dr Jana Biziela w BydgoszczyKlinika Hematologii
-
Katowice, Poland, 40519
- Pratia Onkologia Katowice
-
Kraków, Poland, 30-510
- Pratia MCM Krakow
-
Lublin, Poland, 20-090
- Centrum Onkologii Ziemi Lubelskiej
-
Opole, Poland, 45061
- Szpital Wojewódzki w Opolu
-
Toruń, Poland, 87-100
- Nasz Lekarz Ośrodek Badań Klinicznych
-
Warsaw, Poland, 02781
- Narodowy Instytut Onkologii im. Marii Skłodowskiej-Cuire - Państwowy Instytut Badawczy
-
Wrocław, Poland, 50-367
- Uniwersytecki Szpital Kliniczny Klinika
-
-
Legnica
-
Iwaszkiewicza 5, Legnica, Poland, 59-220
- Wojewodzki Szpital Specjalistyczny
-
-
Lubelskie V
-
Lublin, Lubelskie V, Poland, 20081
- Klinika Hematoonkologii i Transplantacji Szpiku SPSK1 Lublin
-
-
Pomorskie
-
Gdańsk, Pomorskie, Poland, 80214
- Uniwersyteckie Centrum Kliniczne
-
-
Poznan
-
Skorzewo, Poznan, Poland, 60 185
- Centrum Medyczne Pratia Poznan
-
-
-
-
-
Braga, Portugal, 4710-243
- Centro Clínico Académico - Braga (2CA-Braga) (Hospital de Braga)
-
Lisboa, Portugal, 1649035
- Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria
-
Porto, Portugal, 4200-072
- Instituto Português de Oncologia do Porto Francisco Gentil, EPE
-
Porto, Portugal, 4200-319
- Hospital de Sao Joao E.P.E.
-
Vila Nova De Gaia, Portugal, 4434-536
- Centro Hospitalar de Vila Nova de Gaia
-
-
-
-
-
Bucuresti, Romania, 020125
- Spitalul Clinic Colentina
-
Bucuresti, Romania, 030171
- Spitalul Clinic Coltea
-
Bucuresti, Romania, 022328
- Institutul Clinic Fundeni - Centrul de Hematologie si Transplant Medular
-
Cluj-Napoca, Romania, 400015
- Institutul Oncologic "Prof. Dr. Ion Chiricuta" Cluj-Napoca
-
Iasi, Romania, 700483
- Institutului Regional de Oncologie IASI
-
Oradea, Romania, 410469
- Spitalul Clinic Judetean de Urgenta Oradea
-
Targu Mures, Romania, 540136
- Spitalul Clinic Judetean de Urgenta Targu Mures
-
-
Dolj
-
Craiova, Dolj, Romania, 200143
- Spitalul Clinic Municipal Filantropia Craiova
-
-
-
-
-
Penza, Russian Federation, 440071
- Regional Oncology Dispensary
-
St-Petersburg, Russian Federation, 197022
- Academician I.P. Pavlov First St-Petersburg State Medical University
-
-
Omskaya Oblast
-
Omsk, Omskaya Oblast, Russian Federation, 644013
- Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary"
-
-
-
-
-
Barcelona, Spain, 08041
- Hospital de la Santa Creu i Sant Pau
-
L'Hospitalet De Llobregat, Spain, 08908
- Hospital Duran I Reynals
-
Madrid, Spain, 28040
- Hospital Universitario Fundacion Jimenez Diaz
-
Sevilla, Spain, 41013
- Hospital Universitario Virgen del Rocio
-
Sevilla, Spain, 41014
- Hospital Universitario Virgen de Valme
-
-
Asturias
-
Oviedo, Asturias, Spain, 33011
- Hospital Universitario Central de Asturias
-
-
Madrid
-
Majadahonda, Madrid, Spain, 28222
- Hospital Universitario Puerta de Hierro Majadahonda
-
-
Madrid, Comunidad De
-
Madrid, Madrid, Comunidad De, Spain, 28050
- Hospital Universitario HM Sanchinarro
-
-
-
-
-
Changhua, Taiwan, 50544
- Chang Bing Show Chwan Memorial Hospital
-
Kaohsiung, Taiwan, 807
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Taichung, Taiwan, 40447
- China Medical University Hospital
-
Taipei, Taiwan, 10002
- National Taiwan University Hospital
-
Taoyuan City, Taiwan, 333
- Chang Gung Memorial Hospital - Linkou
-
-
-
-
-
Wolverhampton, United Kingdom, WV10 0QP
- New Cross Hospital
-
-
England
-
Birmingham, England, United Kingdom, B9 5SS
- Birmingham Heartlands Hospital
-
-
-
-
California
-
Los Angeles, California, United States, 90027
- California Research Institute
-
Whittier, California, United States, 90603
- Innovative Clinical Research Institute
-
-
Florida
-
Tamarac, Florida, United States, 33321
- Oncology-Hematology Associates of West Broward
-
-
Maine
-
Lewiston, Maine, United States, 04240
- Central Maine Medical Center
-
-
Michigan
-
Grosse Pointe Woods, Michigan, United States, 48236
- Ascension St. John Hospital
-
-
New Jersey
-
Brick, New Jersey, United States, 08724
- New Jersey Center for Cancer Research
-
-
New York
-
Westbury, New York, United States, 11590
- Clinical Research Alliance, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Confirmed diagnosis of CLL/SLL requiring therapy, per iwCLL 2018 criteria
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Adequate organ function
- Platelets greater than or equal to (≥)75 x 10⁹/liter (L) (≥50 × 10⁹/L for patients with evidence of bone marrow infiltrate), hemoglobin ≥8 grams/deciliter (g/dL), and absolute neutrophil count ≥0.75 x 10⁹/L
- Kidney function: Estimated creatinine clearance ≥40 milliliters per minute (mL/min)
Exclusion Criteria:
- Known or suspected Richter's transformation at any time preceding enrollment
- Prior systemic therapy for CLL/SLL
- Presence of 17p deletion
- Central nervous system (CNS) involvement
- Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP])
- Significant cardiovascular disease
- Active hepatitis B or hepatitis C
- Active cytomegalovirus (CMV) infection
- Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
- Known human immunodeficiency virus (HIV) infection, regardless of cluster of differentiation 4 (CD4) count
- Concurrent use of investigational agent or anticancer therapy except hormonal therapy
- Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist
- Vaccination with a live vaccine within 28 days prior to randomization
Patients with the following hypersensitivity:
- Known hypersensitivity, including anaphylaxis, to any component or excipient of pirtobrutinib or bendamustine
- Prior significant hypersensitivity to rituximab
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A (Pirtobrutinib)
Pirtobrutinib administered orally
|
Oral
Other Names:
|
Active Comparator: Arm B (BR)
Bendamustine plus rituximab administered intravenously (IV)
|
IV
Other Names:
IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate progression-free survival (PFS) of pirtobrutinib (Arm A) compared to bendamustine and rituximab (Arm B)
Time Frame: Up to approximately 5 years
|
Assessed by blinded independent review committee (IRC) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 Response Criteria
|
Up to approximately 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the effectiveness of Arm A compared to Arm B in patient-reported disease-related symptoms
Time Frame: Up to approximately 5 years
|
Based on time to worsening of CLL/SLL-related symptoms
|
Up to approximately 5 years
|
To evaluate the effectiveness of Arm A compared to Arm B in patient-reported physical functioning
Time Frame: Up to approximately 5 years
|
Based on time to worsening of physical functioning
|
Up to approximately 5 years
|
To evaluate the effectiveness of Arm A compared to Arm B: Progression-free survival (PFS)
Time Frame: Up to approximately 5 years
|
Assessments of effectiveness include PFS, assessed by investigator
|
Up to approximately 5 years
|
To evaluate the effectiveness of Arm A compared to Arm B: Overall survival (OS)
Time Frame: Up to approximately 5 years
|
Assessments of effectiveness include OS, assessed by investigator
|
Up to approximately 5 years
|
To evaluate the effectiveness of Arm A compared to Arm B: Time to next treatment (TTNT)
Time Frame: Up to approximately 5 years
|
Assessments of effectiveness include TTNT, assessed by investigator
|
Up to approximately 5 years
|
To evaluate the effectiveness of Arm A compared to Arm B: Overall response rate (ORR)
Time Frame: Up to approximately 5 years
|
Assessments of effectiveness include ORR, assessed by investigator and IRC
|
Up to approximately 5 years
|
To evaluate the effectiveness of Arm A compared to Arm B: Duration of Response (DOR)
Time Frame: Up to approximately 5 years
|
Assessments of effectiveness include DOR, assessed by investigator and IRC
|
Up to approximately 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Alex Levy, MD, Loxo Oncology
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 23, 2021
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
May 1, 2026
Study Registration Dates
First Submitted
August 24, 2021
First Submitted That Met QC Criteria
August 24, 2021
First Posted (Actual)
August 27, 2021
Study Record Updates
Last Update Posted (Actual)
April 5, 2024
Last Update Submitted That Met QC Criteria
April 4, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Hematologic Diseases
- Leukemia, B-Cell
- Chronic Disease
- Lymphoma
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Bendamustine Hydrochloride
- Rituximab
- Pirtobrutinib
Other Study ID Numbers
- LOXO-BTK-20023
- J2N-OX-JZNP (Other Identifier: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia
-
National Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingLeukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...United States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedLeukemia | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityCompletedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Celgene CorporationTerminatedChronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteWithdrawnRefractory Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia
-
Mayo ClinicNational Cancer Institute (NCI)CompletedChronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia and other conditionsUnited States
Clinical Trials on Rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
PfizerCompletedRheumatoid ArthritisUnited States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
-
Mabion SAParexelWithdrawn
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUnited States